AUTHORS
Imke E. Karsten, MD, Maud Ngoya2, Raffaella Cerretti, MD3, Gaëlle Guillerm4, Alessandro Maggi5, Christoph Schmid6, Anastasios Karadimitris7, Frederic Baron, MD8, Peter Dreger, Prof. Dr. med.9, Hermann Einsele, MD, PhD10, Zafer Gulbas11, Alessandro Isidori12, Jean-Noel Bastie, MD, PhD13, Ain Kaare14, Zubeyde Nur Ozkurt, MD15, Thomas Pabst16, Antonio Pierini, MD, PhD17, Roland Schroers18, Eva Wagner Drouet19, Georg Lenz, MD20, Charalampia Kyriakou, MD, PhD21, Gandhi Damaj22, Norbert Schmitz23, Ali Bazarbachi24
AFFILIATIONS
1 University Hospital Muenster, Muenster, Germany
2 European Society for Blood and Marrow Transplantation, Paris, France
3 Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, France
4 C.H.R.U de Brest, Brest, France
5 Ospedale Nord Centralino, Taranto, Italy
6 Klinikum Augsburg, Augsburg, Germany
7 Imperial College Hammersmith, London, United Kingdom
8 University of Liege, Liege, Belgium
9 Universitätsklinikum Heidelberg, Heidelberg, Germany
10 Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
11 Anadolu Medical Center Hospital, Kocaeli, Turkey
12 AST Pesaro e Urbino Pesaro, Pesaro, Italy
13 CHU de Dijon, Dijon, France
14 Tartu University Hospital, Tartu, Estonia
15 Gazi University, Faculty of Medicine, Ankara, Turkey
16 University Hospital Bern, Bern, Switzerland
17 University of Perugia, Perugia, Italy
18 Ruhr-University Bochum, Bochum, Germany
19 University Medical Center Mainz, Mainz, Germany
20 University Hospital Muenster, Muenster, Germany
21 University College London Hospitals NHS Foundation Trust, London, United Kingdom
22 Caen University Hospital, Caen, France
23 University Hospital Muenster, Muenster, Germany
24 American University of Beirut Medical Center, Beirut, Lebanon
ABSTRACT
Introduction
Cutaneous T-cell lymphomas (CTCL) are rare with an estimated incidence of 6-10 cases per million. The most common subtypes are mycosis fungoides (MF) and Sézary syndrome (SS). Autologous stem cell transplantation (ASCT) has been used in selected patients (pts) with advanced CTCL, although its role in today`s treatment algorithm remains ill-defined because data on outcomes after ASCT are very limited. We therefore analyzed EBMT registry data to evaluate the efficacy of ASCT in pts with MF and SS.
Methods
We conducted a retrospective analysis of EBMT registry data. The following inclusion criteria were applied: adult patients with MF or SS, HDCT/ASCT between 2004 and 2024. Outcome data were calculated from the day of transplantation until the respective event. Progression-free survival (PFS) was the primary endpoint of this analysis. We used Kaplan-Meier method to calculate PFS, overall survival (OS), and cumulative to estimate relapse incidence (RI), and non-relapse mortality (NRM) for all pts and for patients in remission. To compare the cohorts (MF vs. SS), the log-rank test was used for OS and PFS and the Gray test was used for RI and NRM.
Results
A total of 88 pts were included in this analysis. Sixty-six pts suffered from MF and 22 pts from SS, their median age was 53 years (range 22.9-70.5), 27 pts were female. Disease status at ASCT was progressive disease (PD) in 17 pts (20.0%), stable disease (SD) in 2 pts (2.4%), partial remission in 35 pts (41.2%), and complete remission in 26 patients (30.6%). The majority of pts (60.6%) received BEAM high-dose therapy (BCNU, etoposide, cytosine-arabinoside, melphalan) or variants prior to ASCT. The median time from diagnosis to HDCT/ASCT was 30.7 months.
With a median follow-up of 4.7 years (95% CI: 3.0 – 6.0 years), the 2-year PFS rate for 88 evaluable pts was 21.5 % (95 % CI: 12.1 – 32.7 %), the 2-year OS rate was 47.5 % (95 % CI: 34.0 – 59.8 %), RI was 71.6% (95% CI: 59.3–80.7%) and the NRM rate was 8.6% (95% CI: 3.7–16.1%). Twenty-six of the patients subsequently underwent an allogeneic transplantation (alloHSCT).
With a median follow-up period of 4.9 years (95% CI: 1.9–5.3 years), the 2-year PFS rate in patients who underwent ASCT while in remission was 41.3% (95% CI: 20.2–61.4%), the 2-year OS was 68.6% (95% CI: 42.5–84.7%), RI was 50.1% (95% CI: 26.2.3–70.0%) and NRM rate was 8.6% (95% CI: 1.4–24.4%). A comparison of the MF and SS groups revealed a numerical difference in the two-year PFS rates (15.6% versus 32.5%); however, this difference was not statistically significant (p = 0.31). No significant differences were observed in OS, RI or NRM either.
Conclusions
In this largest series reported to date, ASCT for pts with advanced CTCL resulted in poor disease control and disappointing PFS and OS. Pts in remission before ASCT showed more promising survival rates. These findings indicate a limited role for ASCT in CTCL. Pts without other treatment options and not eligible for alloHSCT may be considered candidates for ASCT especially if in remission before transplantation.
DISCLOSURES
Imke E. Karsten, MD: Kite/Gilead, BeOne - Other (including travel support); Kite/Gilead, BeOne - Honoraria